We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment.
- Authors
Tae Heung Kang; Jung Hwa Park; Andrew Yang; Hyun Jin Park; Sung Eun Lee; Young Seob Kim; Gun-Young Jang; Farmer, Emily; Lam, Brandon; Yeong-Min Park; Chien-Fu Hung
- Abstract
The interaction between immune cells and phosphatidylserine (PS) molecules exposed on the surface of apoptotic-tumor bodies, such as those induced by chemotherapies, contributes to the formation of an immunosuppressive tumor microenvironment (TME). Annexin A5 (AnxA5) binds with high affinity to PS externalized by apoptotic cells, thereby hindering their interaction with immune cells. Here, we show that AnxA5 administration rescue the immunosuppressive state of the TME induced by chemotherapy. Due to the preferential homing of AnxA5 to the TME enriched with PS+ tumor cells, we demonstrate in vivo that fusing tumor-antigen peptide to AnxA5 significantly enhances its immunogenicity and antitumor efficacy when administered after chemotherapy. Also, the therapeutic antitumor effect of an AnxA5-peptide fusion can be further enhanced by administration of other immune checkpoint inhibitors. Our findings support the administration of AnxA5 following chemotherapy as a promising immune checkpoint inhibitor for cancer treatment.
- Subjects
IMMUNE checkpoint inhibitors; CANCER treatment; TREATMENT effectiveness; TUMOR microenvironment; MOLECULES
- Publication
Nature Communications, 2020, Vol 11, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-020-14821-z